Crohn’s disease is an inflammatory bowel disease which may affect gastrointestinal tract from mouth to anus, and has a wide variety of symptoms. Mycobacterium avium subspecies paratuberculosis (MAP) is believed to be associated with Cronh’s disease.
Professor Dr. Saleh Naser, UFC College of Medicine, believes that MAP is the cause of the disease. He said, "Crohn's disease affects more than 750,000 Americans, yet traditional treatments only address the symptoms of inflammation and not the cause." He further added, "I have seen case studies where patients' lives have been restored following treatment, which removes MAP. I have high hopes that this clinical trial may lead to finding a cure."
Dr. Saleh Naser will soon conduct clinical trials on a new antibiotic therapy acquired by RedHill Biopharma for curing the disease.
240 participants will be recruited for this double blind clinical trial.
It would be great if new antibiotics treatment to Crohn proved working. The incidence of this disorder in Europe (as well as in other parts of the world) is still rising and patients need new effective treatments to this problem. Also in many cases this condition is not well diagnosed and people come too late and they need to undergo the surgery, which always has a certain negative impact on their quality of life. Good luck with the study.
ReplyDelete